Paul Percheson

Learn More
BACKGROUND Subcutaneous administration of Eprex(®) (epoetin alfa) in patients with chronic kidney disease (CKD) was contraindicated in the European Union between 2002 and 2006 after increased reports of anti-erythropoietin antibody-mediated pure red cell aplasia (PRCA). The Prospective Immunogenicity Surveillance Registry (PRIMS) was conducted to estimate(More)
Three strains of Streptococcus pneumoniae with low-level resistance to penicillin, one strain with resistance to penicillin, and three strains susceptible to penicillin were compared. The three susceptible strains had very similar patterns of penicillin-binding components (PBCs) as detected by fluorography after sodium dodecyl sulfate-polyacrylamide gel(More)
We have found that our MDCK-derived cell line (BV-5F1) is non-tumorigenic in tests conducted in accordance with FDA guidelines, and thus may be suitable for producing live, attenuated or inactivated vaccine. The cell line has been extensively tested for the presence of contaminating microorganisms. No infectious agents of viral or other microbial origin(More)
  • 1